Table 4.
Psychopharmacological Treatment in the Baseline and in the Two-year Follow-up Visit
| Baseline (n = 310) |
24 Months (n = 105) |
|
|---|---|---|
| Antipsychotic treatment | ||
| No antipsychotic therapy – no. (%) | 25 (8.1%) | 17 (5.5%) |
| Monotherapy – no. (%) | 217 (70.0%) | 77 (24.8%) |
| Polytherapy – no. (%) | 68 (21.9%) | 11 (3.5%) |
| 2 antipsychotics – no. (%) | 62 (20%) | 10 (3.2) |
| 3 antipsychotics – no. (%) | 5 (1.6%) | 1 (0.3%) |
| 4 antipsychotics – no. (%) | 1 (0.3%) | 0 |
| Chlorpromazine equivalent mean dose – mg/day (SD) | 611.10 ± 449.91 | 346.30 ± 289.06 |
| Subjects with other treatment | ||
| Anticholinergics | 39 (12.6%) | 4 (1.3%) |
| Antidepressants | 41 (13.2) | 18 (5.8%) |
| Mood stabilizers | 40 (12.9%) | 27 (8.7%) |
| Benzodiazepines | 123 (39.7%) | 17 (5.5%) |